期刊名称：PHARMACOEPIDEMIOLOGY AND DRUG SAFETY ISSN： 1053-8569 版本： SCI-CDE 出版频率： Monthly 出版社： WILEY, 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774   出版社网址： http://www3.interscience.wiley.com/ 期刊网址： http://www3.interscience.wiley.com/cgi-bin/jhome/5669 影响因子： 2.89 主题范畴： PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH;    PHARMACOLOGY & PHARMACY 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal      Pharmacoepidemiology and Drug Safety    Copyright © 2005 John Wiley & Sons, Ltd. The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the emerging discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical and legal aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Communication. Particular areas of interest include: design, results, analysis and interpretation of post-marketing surveillance and other studies looking at specific drugs, populations and outcomes methods for detection and evaluation of drug-associated adverse events assessments of risk versus benefit ratios in drug therapy patterns of drug utilization relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines The Publishers recognize the need of journal users to access articles through a variety of channels, and are committed to providing a wide range of options in the future. The Publishers are also aware that new communication media increase the threat to authors' own rights through unauthorized distribution, alteration or attribution. To enable the Publishers to make the published version of articles available as widely as possible, while protecting authors' rights to be associated with their work, it is essential that a Copyright Transfer Agreement form is signed for every article which is to be considered for publication in the journal. The form can be photocopied from the journal, or copies can be obtained on request from the Publisher or printed from this Web site. Inclusion of a signed form with the manuscript at the original submission stage will speed up processing and eventual publication of the article. Abstracting and Indexing Services BIOSIS Previews Cambridge Scientific Abstracts Chemical Abstracts Service Current Contents®/Clinical Medicine (ISI) Elsevier BIOBASE/Current Awareness in Biological Sciences EMBASE/Excerpta Medica (Elsevier) Index Medicus/MEDLINE International Pharmaceutical Abstracts ISI Alerting Services Medical Documentation Service (ISI) Science Citation Index Expanded (also known as SciSearch®) (ISI) Science Citation Index® (ISI) Statistical Theory and Method Abstracts Instructions to Authors Initial Manuscript Submission. Both initial submissions and revised manuscripts should consist of one paper copy (including copies of tables and illustrations) and an electronic copy, either on disk or as an email attachment. Authors must also supply with their intial submissions: a Conflict of Interest Disclosure Form, completed by each author. A copy of the form to be used (which may be photocopied) can be found in each volume of Pharmacoepidemiology and Drug Safety. Copies may also be obtained from the journal editor or publisher. a Copyright Transfer Agreement with original signature of each author (see section below). A copy of the agreement to be used (which may be photocopied) can be found in each volume of Pharmacoepidemiology and Drug Safety. Copies may also be obtained from the journal editor or publisher. Only original signatures are acceptable for the two documents above; faxed copies of signatures cannot be accepted. permission letters - it is the author's responsibility to obtain written permission to reproduce (in all media, including electronic) material which has appeared in another publication using the Wiley Permission Request Form. Submit the manuscript to either Professor Strom (manuscripts from North and South America) or Professor Mann (the rest of the world). All communications will be acknowledged. Professor Ronald D. Mann, 42 Hazleton Way, Waterlooville, Hampshire, PO8 9BT, UK. Tel: +44 02392 597220. Fax: +44 02392 571073. E-mail: DrMann@manorcottage.fsbusiness.co.uk Professor Brian Strom, University of Pennsylvania School of Medicine, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, 824 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA. Tel: 215 898 2368. Fax: 215 573 5315. E-mail: jkinman@cceb.med.upenn.edu Submission of a manuscript will be held to imply that it contains original unpublished work and is not being submitted for publication elsewhere at the same time. Submitted material will not be returned to the author. Electronic submission. Disks should be PC formatted; write on the disk the software package used (Word is preferred), the name of the first author, and the name of the journal. Illustrations must be submitted in electronic format where possible. Save each figure as a separate file, in TIFF, EPS, or PDF. Write on the disk the software package used to create them. Email attachments are also acceptable provided the total file size does not exceed 2Mb. Manuscript style. All submissions must have a title, be printed on one side of the paper, be double-line spaced and have a margin of 3 cm all round. Illustrations and tables must be printed on separate sheets, and not be incorporated into the text. The title page must list the full title, short title and names and affiliations of all authors. Give the full address, including email, telephone and fax, of the author who is to check the proofs. Include the name(s) of any sponsor(s) of the research contained in the paper, along with grant number(s). Supply a structured abstract of up to 250 words for all articles. An abstract is a concise summary of the whole paper, not just the conclusions, and is understandable without reference to the rest of the paper. Structure abstracts using the following headings: Purpose, Methods, Results and Conclusions. The abstract should contain no citation to other published work. Include between three and 10 key words that describe your paper for indexing purposes. Up to five bulleted “take-home?messages should be included. Expert reviews of ‘hot topics?and controversies are welcome. Reviews should be of a critical nature, discussing all sides of a question in a balanced manner. Experts considering offering such a review should feel free to contact either of the editors, as appropriate, in order to avoid unnecessary effort. Authors must indicate how their data collection methods have complied with Privacy & Confidentiality requirements applicable to their locales. Reviews of books and other media may be submitted only at the invitation of the editors. However, suggestions are welcome. A fast-track review and publication process are now in place for particularly time-sensitive findings. The editor should be contacted to begin this process. Authors are invited to propose reviewers who have special competence to review their work. Authors may also ask that, due to a possible conflict of interest, named members of the Editorial Board or other individuals should not be selected to review a particular submission. The editors will pay close attention to such requests, but must reserve to themselves the final choice of reviewers. The cover letter with each submission should designate one author as the presiding or corresponding author. This author should ensure that all co-authors have materially and meaningfully contributed to the study and are, in public, able to speak of the work that has been done. Other colleagues should be properly acknowledged, but should not be listed as co-authors. The editors recognize that in many major pharmacoepidemiology studies the acknowledgement list may be very long indeed. Abbreviations: All abbreviations should be preceded the first time they appear by the full name except the SI symbols for units which are to be used without explanation. Identify Greek letters and unusual symbols separately in the margin. Distinction should be made between capital and lower case letters; between the letter O and zero, between I and the number one and prime, between k and kappa. Nomenclature: Use generic or chemical names for all compounds. Indicate sources of unusual materials and chemicals, and the manufacturer and model of equipment used. Identify materials and products in the text by the generic name followed by the trade name in brackets. Units: Use SI units of measurement. If other systems are employed give conversion factors. Reference style. References should be cited by superscript numbers and listed at the end of the paper in the order in which they appear in the text. All references must be complete and accurate. Online citations should include the date of access. Use Index Medicus abbreviations for journal names. For correct abbreviations visit http://www.ncbi.nlm.nih.gov/entrez/jrbrowser.cgi. If necessary, cite unpublished or personal work in the text but do not include it in the reference list. References should be listed in the following style: Journals: 1. Johnson JE and Lauver DR. Alternative explanations of coping with stressful experiences associated with physical illness. Adv Nurs Sci 1989; 11: 39-52. Books: 2. Meichenbaum D and Turk D. Facilitating Transplant Adherence: A Practitioner's Guide. Plenum Press: New York, NY, 1987; 44. Chapters in Books: 3. Cramer JA and Mattson RH. Monitoring compliance with antiepileptic drug therapy. In Patient Compliance in Medical Practice and Clinical Trials. Cramer JA and Spiker B (eds). Raven Press: New York, NY, 1991; 123-138. Illustrations. Supply each illustration on a separate sheet. Write the lead author's name and the figure number on the reverse, and make sure that the top of the figure is clearly indicated. Supply original photographs; photocopies or previously printed material will not be used. Line artwork must be high-quality laser output (not photocopies); tints should be avoided. Lettering must be of a reasonable size that would still be clearly legible upon reduction, and consistent within each figure and set of figures. Please supply artwork at the intended size for printing. It should be sized to the text width of 75mm to fit a single column and 155mm for a double column. Printing colour illustrations in the journal is unusual and the cost will be charged to the author. If colour illustrations are supplied electronically in either TIFF or EPS format, they may be used in the PDF of the article at no cost to the author, even if this illustration was printed in black and white in the journal. The PDF will appear on the Wiley InterScience site. Copyright. To enable the publisher to disseminate the author's work to the fullest extent, each author must sign a Copyright Transfer Agreement, transferring copyright in the article from the author to the publisher. Further Information. Proofs will be sent to the author for checking. This stage is to be used only to correct errors that may have been introduced during the production process. Prompt return of the corrected proofs, preferably within two days of receipt, will minimise the risk of the paper being held over to a later issue. 25 complimentary offprints will be provided to the author who checked the proofs, unless otherwise indicated. Further offprints and copies of the journal may be ordered. There is no page charge to authors. Editorial Board EDITOR-IN-CHIEF Professor Ronald D. Mann 42 Hazleton Way Waterlooville Hampshire PO8 9BT, UK REGIONAL EDITOR FOR THE AMERICAS Professor Brian Strom University of Pennsylvania Medical Center Director, Center for Clinical Epidemiology and Biostatistics 824 Blockley Hall, 423 Guardian Drive Philadelphia, PA 19104-6021, USA ASSOCIATE EDITORS W. Bilker University of Pennsylvania School of Medicine PA, USA C. van Boxtel Department of Clinical Pharmacology Academic Medical Centre Amsterdam, The Netherlands A. Breckenridge The University of Liverpool UK S. Evans Medicines Control Agency London, UK J. Farrar University of Pennsylvania School of Medicine PA, USA R. Gross Center for Clinical Epidemiology and Biostatistics University of Pennsylvania Medical Center PA, USA G. Hall Ravenscroft Park, Barnet, UK J. Hasford University of Munich, Germany S. Hennessy University of Pennsylvania School of Medicine PA, USA S. Kimmel University of Pennsylvania School of Medicine PA, USA J. Lewis University of Pennsylvania Medical Center USA G. Macones University of Pennsylvania School of Medicine PA, USA D. Margolis University of Pennsylvania School of Medicine PA, USA J. Metlay University of Pennsylvania School of Medicine PA, USA N. Moore Universit¨¦ Victor Segalen, Bordeaux, France M.D. Rawlins Department of Pharmacological Sciences University of Newcastle upon Tyne, UK M.D. Sammel University of Pennsylvania School of Medicine, PA, USA M. Thorogood Warwick Medical School University of Warwick, UK J. Urquhart Masstricht University, Netherlands EDITORIAL BOARD E.B. Andrews Glaxo Wellcome, Inc Research Triangle Park, NC, USA B. B¨¦gaud Universit¨¦ Victor Segalen Bordeaux, France D.R. Bass Bfarm, Bonn, Germany E.A. Bortnichak Berlex Laboratories Wayne, NJ, USA D. Chanter Statisfaction Statistical Consultancy Ltd Bexhill-on-Sea, UK D. Chen CKW Consulting, Gloucester Massachusetts, MA, USA G.S. Dieck Pfizer Inc., New York, USA N.R. Dunn Department of Primary Medical Care School of Medicine, University of Southampton, UK R. Edwards WHO Collaborating Centre for International Drug Monitoring Uppsala, Sweden G.A. Faich President, Pharmaceutical Safety Assessments, Inc., Narberth, PA, USA C.H. Goldsmith Department of Clinical Epidemiology & Biostatistics, McMaster University Centre for Evaluation of Medicine St. Joseph's Hospital Hamilton, Canada A.C. van Grootheest Netherlands Pharmacovigilance Centre LAREB,'s-Hertogenbosch The Netherlands P. Hannaford Foresterhill Health Centre Aberdeen, UK D.A. Henry Royal Newcastle Hospital N.S.W. Australia Botley, UK J. Jones The Degge Group Ltd, Arlington, VA, USA G. Kreutz Bfarm, Bonn, Germany K. Kubota Faculty of Medicine University of Tokyo, Japan T. Kusunoki Faculty of Medicine University of Tokyo, Japan G. Lagier CRPV, Paris, France D.H. Lawson Department of Clinical Pharmacology Royal Infirmary, Glasgow, UK V.K. Lepakhin Senior Clinical Adviser, Essential Drugs and Medicines Policy WHO and Russian University of People's Friendship Moscow, Russia H.G.M. Leufkens Utrecht Institute for Pharmaceutical Sciences The Netherlands M. Lewis EPEs Epidemiology, Pharmacoepidemiology & Systems Research Berlin, Germany E. Loupi Aventis Pasteur, France H. McGavock Director, Drug Utilization Research Unit Belfast, UK J. Marley The University of Newcastle NSW, Australia R. Martin University of Bristol, UK R.H.B. Meyboom Netherlands Pharmacovigilance Foundation LAREB Tilburg, The Netherlands J.L. Montastruc Hopitaux de Toulouse, Facult¨¦ de M¨¦decine Toulouse, France C. Ineke Neutel University of Ottawa, Institute on Health for the Elderly, Ottawa, Canada W. Nimmo Inveresk Research Group Ltd Edinburgh, UK M. Ollagnier CRPV, Hopital de Bellevue Saint-Etienne, France R. Platt Harvard Medical School Boston, USA J. Raine Medicines Control Agency, London R. Royer Centre de Pharmacovigilance Hôpital Central, Nancy France S. Shakir Drug Safety Research Unit Southampton, UK S.P. Spielberg Dartmouth Medical School Hanover, NH, USA M. Stephens Bishop's Stortford, UK A. Stergachis University of Washington Seattle, USA S. Suissa McGill University and Royal Victoria Hospital Montreal, Canada G. Velo WHO Reference Centre for Education and Communication in International Drug Monitoring, Verona, Italy M. Vessey Department of Public Health and Primary Care Radcliffe Infirmary, Oxford, UK A. Walker Harvard School of Public Health Boston, USA B.-E. Wiholm Merck & Co. Inc, West Point, PA, USA A. Wiles IBM Life Sciences, Cary, NC, USA